Literature DB >> 17563866

[Lethal course after chemotherapy with docetaxel. Acute liver failure with accompanying erythema multiforme major].

C-H Ohlmann1, S Kohlmorgen, D Sahi, U Engelmann, A Heidenreich.   

Abstract

We report on the lethal course of a patient receiving low-dose, weekly docetaxel who developed acute liver failure accompanied by a Stevens-Johnson syndrome. After receiving the fifth application of his chemotherapy, the patient was admitted to hospital because of neutropenia and severe erythema. The course worsened towards an acute liver failure and an erythema multiforme major. Despite an interdisciplinary approach, the further course could not be influenced and the patient died 6 weeks after admission due the toxicity of docetaxel. This case report underlines the spectrum of toxicity of docetaxel even in the low-dose weekly schedule.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17563866     DOI: 10.1007/s00120-007-1367-9

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  7 in total

1.  Reversible hepatic coma possibly induced by docetaxel treatment.

Authors:  Y M Chen; C M Tsai; R P Perng
Journal:  Lung Cancer       Date:  2001 Feb-Mar       Impact factor: 5.705

2.  [Fulminant hepatocellular necrosis following administration of docetaxel].

Authors:  E Tomassini; J Muhizi; K al Raheb; G Steinbach; M Bemer; C Platini
Journal:  Presse Med       Date:  2001-04-07       Impact factor: 1.228

3.  Acute severe steatohepatitis related to prednisolone therapy.

Authors:  S P Dourakis; V A Sevastianos; P Kaliopi
Journal:  Am J Gastroenterol       Date:  2002-04       Impact factor: 10.864

Review 4.  EAU guidelines on prostate cancer.

Authors:  G Aus; C C Abbou; M Bolla; A Heidenreich; H-P Schmid; H van Poppel; J Wolff; F Zattoni
Journal:  Eur Urol       Date:  2005-10       Impact factor: 20.096

5.  Erythema multiforme major following docetaxel.

Authors:  Christina Moisidis; Volker Möbus
Journal:  Arch Gynecol Obstet       Date:  2004-07-09       Impact factor: 2.344

6.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Authors:  Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

7.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

  7 in total
  3 in total

1.  Life-threatening dermatologic adverse events in oncology.

Authors:  Alyx C Rosen; Yevgeniy Balagula; Dennis W Raisch; Vishvas Garg; Beatrice Nardone; Nicole Larsen; Jennifer Sorrell; Dennis P West; Milan J Anadkat; Mario E Lacouture
Journal:  Anticancer Drugs       Date:  2014-02       Impact factor: 2.248

Review 2.  Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies.

Authors:  Chau Yee Ng; Chun-Bing Chen; Ming-Ying Wu; Jennifer Wu; Chih-Hsun Yang; Rosaline Chung-Yee Hui; Ya-Ching Chang; Chun-Wei Lu
Journal:  J Immunol Res       Date:  2018-01-17       Impact factor: 4.818

3.  Docetaxel-Induced Stevens-Johnson Syndrome in a Patient with Metastatic Prostate Adenocarcinoma.

Authors:  Osama Diab; Dan Mcentire; Thamer Kassim; Ali Nayfeh; Abdel Rahman Dajani; Mitchell Kerfeld; Jonathon Campbell; Adbullah Alsuwaidan; Mahmoud Abu Hazeem; Maryam Gbadamosi-Akindele
Journal:  Case Rep Oncol Med       Date:  2019-01-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.